文献速递冠心病

高敏肌钙蛋白检测在疑似急性冠脉综合征中的不一致性

Discordance of High-Sensitivity Troponin Assays in Patients With Suspected Acute Coronary Syndromes.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

该研究基于ROMICAT I和II试验中624例疑似ACS患者,比较三种高敏肌钙蛋白检测在分析基准和0/2小时管理推荐上的一致性。结果显示样本分析基准分类一致性低,管理推荐一致性为74.8%,且被推荐出院的患者中仍有部分存在诊断阳性发现或ACS。

要点

  • 三种hs-cTn检测对同一样本的分析基准分类一致性低。
  • 0/2小时管理推荐在三种检测间的一致性为74.8%。
  • 被推荐出院的患者中仍有2.8%至4.3%存在ACS。

核心结论

  • 不同hs-cTn检测在分析基准分层和患者管理推荐上存在显著差异,可能导致不同的管理决策。

研究设计与样本

  • 研究纳入ROMICAT I和II试验中疑似ACS患者624例,共1027份血样,分别用Roche、Abbott和Siemens三种hs-cTn检测测量。

主要发现

  • 样本按<LOD分类的比例在Roche、Abbott和Siemens分别为56.3%、10.4%和41.2%(p<0.001)。
  • 样本按LOD-99th百分位分类的比例分别为36.5%、83.5%和52.6%(p<0.001)。
  • 仅37.4%的样本被三种检测归入相同的分析基准类别。
  • 有系列样本的242例患者中,管理推荐一致性为74.8%。
  • 被推荐出院的患者中19.6%至21.1%有诊断试验阳性发现,2.8%至4.3%存在ACS。

关键数值与推荐

  • 分析基准分为<LOD、LOD-99th百分位和>99th百分位三类。
  • 管理推荐基于0/2小时算法分为排除、观察和纳入三类。

临床怎么用

  • 临床医生应知晓不同hs-cTn检测在中间风险患者中的分层差异,避免仅凭单一检测结果做管理决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-sensitivity cardiac troponin (hs-cTn) assays have different analytic characteristics. OBJECTIVES: The goal of this study was to quantify differences between assays for common analytical benchmarks and to determine whether they may result in differences in the management of patients with suspected acute coronary syndrome (ACS). METHODS: The authors included patients with suspected ACS enrolled in the ROMICAT (Rule Out Myocardial Infarction/Ischemia Using Computer Assisted Tomography) I and II trials, with blood samples taken at emergency department presentation (ROMICAT-I and -II) or at 2 and 4 h thereafter (ROMICAT-II). hs-cTn concentrations were measured using 3 assays (Roche Diagnostics, Elecsys 2010 platform; Abbott Diagnostics, ARCHITECT i2000SR; Siemens Diagnostics, HsVista). Per blood sample, we determined concordance across analytic benchmarks (<limit of detection [<LOD]/LOD-99th percentile/>99th percentile). Per-patient, the authors determined concordance of management recommendations (rule-out/observe/rule-in) per the 0/2-h algorithm, and their association with diagnostic test findings (coronary artery stenosis >50% on coronary computed tomography angiography or inducible ischemia on perfusion imaging) and ACS. RESULTS: Among 1,027 samples from 624 patients (52.8 ± 10.0 years; 39.4% women), samples were classified as <LOD (56.3% vs. 10.4% vs. 41.2%; p < 0.001), LOD-99th percentile (36.5% vs. 83.5% vs. 52.6; p < 0.001), >99th percentile (7.2% vs. 6.0% vs. 6.2%) by Roche, Abbott, and Siemens, respectively. A total of 37.4% (n = 384 of 1,027) of blood samples were classified into the same analytical benchmark category, with low concordance across benchmarks (<LOD 11.1%; LOD-99th percentile 29.3%; >99th percentile 43.6%). Serial samples were available in 242 patients (40.1% women; mean age: 52.8 ± 8.0 years). The concordance of management recommendations across assays was 74.8% (n = 181 of 242) considering serial hs-cTn measurements. Of patients who were recommended to discharge, 19.6% to 21.1% had positive diagnostic test findings and 2.8% to 4.3% had ACS at presentation. CONCLUSIONS: Caregivers should be aware that there are significant differences between hs-cTn assays in stratifying individual samples and patients with intermediate likelihood of ACS according to analytical benchmarks that may result in different management recommendations. (Rule Out Myocardial Infarction by Computer Assisted Tomography [ROMICAT]; NCT00990262) (Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography [ROMICAT-II]; NCT01084239).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Karády J, Mayrhofer T, Ferencik M, et al. Discordance of High-Sensitivity Troponin Assays in Patients With Suspected Acute Coronary Syndromes. J Am Coll Cardiol. 2021. PMID: 33766254. doi:10.1016/j.jacc.2021.01.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。